Woman looking up banner image

Latest News and Events

Home /

Newsroom

February 24, 2026

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

February 5, 2026

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

January 27, 2026

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

January 20, 2026

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

January 8, 2026

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

January 7, 2026

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

January 6, 2026

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

January 6, 2026

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

January 5, 2026

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

December 23, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

December 15, 2025

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

December 8, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

December 2, 2025

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

December 1, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

November 25, 2025

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

November 24, 2025

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

November 18, 2025

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

November 6, 2025

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

November 4, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

October 28, 2025

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

October 21, 2025

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

October 7, 2025

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

September 11, 2025

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

September 10, 2025

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

September 2, 2025

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

August 27, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

August 13, 2025

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

August 7, 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

August 1, 2025

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

July 28, 2025

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

July 24, 2025

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 23, 2025

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

July 21, 2025

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

July 8, 2025

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

June 23, 2025

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

June 2, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

May 29, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

May 12, 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

May 7, 2025

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

April 30, 2025

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

April 15, 2025

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

April 4, 2025

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

March 10, 2025

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

March 6, 2025

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

February 28, 2025

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

February 25, 2025

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

February 10, 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

February 10, 2025

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

January 22, 2025

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

January 17, 2025

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

December 23, 2024

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

December 19, 2024

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

December 11, 2024

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

December 3, 2024

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

December 2, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

November 26, 2024

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

November 26, 2024

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs

November 18, 2024

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

November 18, 2024

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

November 5, 2024

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results

November 4, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences

November 1, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome

October 14, 2024

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

September 23, 2024

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

September 10, 2024

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

September 2, 2024

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

August 21, 2024

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

August 14, 2024

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies

August 8, 2024

Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results

August 8, 2024

Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street

July 29, 2024

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 24, 2024

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

June 25, 2024

Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial

June 24, 2024

Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE

June 3, 2024

Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome

May 31, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences

May 29, 2024

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia

May 28, 2024

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia

May 20, 2024

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

May 9, 2024

Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results

May 2, 2024

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma

April 29, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences

April 26, 2024

Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars

April 24, 2024

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results

April 24, 2024

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

April 7, 2024

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

April 1, 2024

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

March 25, 2024

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

March 8, 2024

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

March 4, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences

February 6, 2024

Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results

January 22, 2024

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results

January 5, 2024

Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million

January 3, 2024

Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock

December 29, 2023

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

December 21, 2023

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease

December 20, 2023

Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

November 29, 2023

Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results

November 28, 2023

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

November 21, 2023

Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference

November 16, 2023

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results

November 13, 2023

Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

November 6, 2023

Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference

November 2, 2023

Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023

October 31, 2023

GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen

October 3, 2023

Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences

September 27, 2023

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

September 11, 2023

Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023

September 1, 2023

Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences

August 7, 2023

Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results

July 24, 2023

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results

July 17, 2023

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy

July 6, 2023

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

June 27, 2023

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1

June 24, 2023

Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease

June 6, 2023

Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences

June 1, 2023

Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics

May 23, 2023

Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH

May 16, 2023

Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

May 15, 2023

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

May 2, 2023

Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results

April 25, 2023

Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect

April 18, 2023

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results

April 12, 2023

Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics

April 4, 2023

First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead

April 3, 2023

Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK

March 31, 2023

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

March 20, 2023

Arrowhead Receives FDA Fast Track Designation for ARO-APOC3

March 3, 2023

Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference

February 28, 2023

Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

February 15, 2023

Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

February 6, 2023

Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results

February 2, 2023

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis

January 25, 2023

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results

January 9, 2023

Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

December 21, 2022

Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

December 21, 2022

Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

December 20, 2022

Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen

December 15, 2022

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

December 8, 2022

Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

November 28, 2022

Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results

November 21, 2022

Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences

November 14, 2022

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results

November 9, 2022

Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones

November 7, 2022

Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline

October 13, 2022

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

October 11, 2022

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3

September 1, 2022

Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences

August 17, 2022

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis

August 4, 2022

Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results

July 20, 2022

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results

July 8, 2022

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 5, 2022

Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

June 27, 2022

Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

June 7, 2022

Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences

May 26, 2022

Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics

May 10, 2022

Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results

May 9, 2022

Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives

May 2, 2022

Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors

May 2, 2022

Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences

April 27, 2022

Arrowhead Pharmaceuticals to Host Pulmonary R&D Day

April 26, 2022

Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia

April 25, 2022

Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market

April 20, 2022

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results

April 6, 2022

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

April 1, 2022

Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences

March 24, 2022

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases

March 15, 2022

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma

February 24, 2022

Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

February 18, 2022

Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

February 17, 2022

Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

February 2, 2022

Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results

January 24, 2022

Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline

January 21, 2022

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results

January 12, 2022

Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

December 20, 2021

Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities

December 17, 2021

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

November 30, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences

November 22, 2021

Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results

November 22, 2021

Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD

November 17, 2021

Arrowhead Announces JNJ-75220795 in Development for NASH

November 15, 2021

Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection

November 15, 2021

Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021

November 12, 2021

Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting

November 12, 2021

Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting

November 1, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results

November 1, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences

October 25, 2021

Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases

October 12, 2021

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases

September 30, 2021

Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia

September 29, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences

September 28, 2021

Arrowhead Earns $10 Million Phase 1 Milestone Payment

September 1, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences

August 5, 2021

Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results

July 29, 2021

Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease

July 14, 2021

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 14, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results

July 6, 2021

Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

July 2, 2021

Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study

June 30, 2021

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

June 26, 2021

Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress

June 25, 2021

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

June 23, 2021

Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress

June 21, 2021

Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout

June 21, 2021

Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout

June 3, 2021

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia

June 2, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

May 18, 2021

Arrowhead Earns $10 Million Option Exercise Fee

May 12, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

May 4, 2021

Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results

April 28, 2021

Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease

April 16, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

April 15, 2021

Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform

March 1, 2021

Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

February 4, 2021

Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results

January 25, 2021

Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia

January 19, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results

December 7, 2020

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

November 30, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

November 25, 2020

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda

November 23, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results

November 13, 2020

Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020

November 13, 2020

Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease

November 9, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

November 4, 2020

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3

November 2, 2020

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results

October 8, 2020

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease

September 30, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference

September 24, 2020

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

September 16, 2020

Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment

September 8, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences

September 8, 2020

Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors

August 31, 2020

Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020

August 28, 2020

Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress

August 18, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences

August 18, 2020

Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

August 11, 2020

Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis

August 5, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results

July 29, 2020

Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890

July 28, 2020

Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis

July 24, 2020

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

July 9, 2020

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis

July 8, 2020

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Third Quarter Results

May 28, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences

May 7, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results

May 1, 2020

Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given

May 1, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences

April 22, 2020

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Second Quarter Results

April 10, 2020

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis

March 17, 2020

Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread

March 17, 2020

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

March 3, 2020

Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH

March 2, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming March 2020 Conferences

February 5, 2020

Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3

February 5, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results

January 22, 2020

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results

January 6, 2020

Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer

December 20, 2019

Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

December 16, 2019

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

December 16, 2019

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease

December 13, 2019

Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors

December 11, 2019

Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

December 6, 2019

Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million

December 4, 2019

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock

December 2, 2019

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock

November 26, 2019

Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences

November 25, 2019

Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results

November 18, 2019

Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019

November 15, 2019

Arrowhead Pharmaceuticals Announces Planned Management Transition

November 11, 2019

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results

November 8, 2019

Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019

October 31, 2019

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference

October 18, 2019

Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics

October 2, 2019

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

September 30, 2019

Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences

September 20, 2019

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

September 16, 2019

Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3

August 30, 2019

Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences

August 28, 2019

Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection

August 8, 2019

Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

August 5, 2019

Arrowhead Pharmaceuticals Reports Fiscal 2019 Third Quarter Results

July 24, 2019

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results

July 16, 2019

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3

July 8, 2019

Arrowhead Pharmaceuticals to Participate in Roth RNA Revolution Conference

June 27, 2019

Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease

June 21, 2019

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

June 21, 2019

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3

May 31, 2019

Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences

May 8, 2019

Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results

May 2, 2019

Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences

April 24, 2019

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Second Quarter Results

April 24, 2019

Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen

April 15, 2019

Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

April 12, 2019

Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™

April 12, 2019

Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™

March 29, 2019

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

March 18, 2019

Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

March 11, 2019

Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia

March 1, 2019

Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences

February 7, 2019

Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results

January 24, 2019

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results

January 7, 2019

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia

January 7, 2019

Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases

December 17, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

December 11, 2018

Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results

November 27, 2018

Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results

November 9, 2018

Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018

November 9, 2018

Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018

November 1, 2018

Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences

October 31, 2018

Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen

October 16, 2018

Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics

October 15, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3

October 11, 2018

Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018

October 4, 2018

Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen

September 25, 2018

Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences

September 24, 2018

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

September 21, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

September 6, 2018

Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit

August 31, 2018

Arrowhead Completes Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

August 30, 2018

Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences

August 7, 2018

Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results

August 1, 2018

Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen

July 24, 2018

Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Third Quarter Results

June 29, 2018

Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference

June 27, 2018

Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

June 18, 2018

Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

June 8, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

May 30, 2018

Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV

May 30, 2018

Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences

May 21, 2018

Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis

May 14, 2018

Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV

May 11, 2018

Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline

May 8, 2018

Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results

May 1, 2018

Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics

April 24, 2018

Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results

April 11, 2018

Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™

March 28, 2018

Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™

March 27, 2018

Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B

March 20, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

March 12, 2018

Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

March 6, 2018

Arrowhead to Present at Barclays Global Healthcare Conference 2018

February 22, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

February 15, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT

February 15, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B

February 9, 2018

Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results

February 2, 2018

Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results

January 22, 2018

Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million

January 18, 2018

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock

January 17, 2018

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock

December 27, 2017

Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors

December 22, 2017

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV

December 20, 2017

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AAT

December 18, 2017

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(C)(4)

December 12, 2017

Arrowhead Pharmaceuticals Reports Fiscal 2017 Year End Results

December 6, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy

December 5, 2017

Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results

November 14, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference

October 23, 2017

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

October 23, 2017

Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017

October 10, 2017

Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting®

October 3, 2017

Arrowhead to Present at Chardan Gene Therapy Conference

September 27, 2017

Arrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment

September 14, 2017

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM™ Platform and Lead RNAi-based Drug Candidates

September 11, 2017

Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference

September 1, 2017

Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies

August 3, 2017

Arrowhead Reports Fiscal 2017 Third Quarter Results

July 27, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results

June 9, 2017

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

May 3, 2017

Arrowhead Reports Fiscal 2017 Second Quarter Results

April 26, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results

April 24, 2017

Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data at The International Liver Congress™

April 20, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™

April 5, 2017

Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™

March 23, 2017

Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement

February 6, 2017

Arrowhead Reports Fiscal 2017 First Quarter Results

January 30, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results

January 9, 2017

Arrowhead Provides Response to New Minority Shareholder Announcement

December 14, 2016

Arrowhead Reports Fiscal 2016 Year End Results

December 7, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results

November 29, 2016

Arrowhead Pharmaceuticals Focuses Resources on Subcutaneous and Extra-Hepatic RNAi Therapeutics

November 21, 2016

Arrowhead Pharmaceuticals Announces Closing of License and Collaboration Agreement with Amgen

November 14, 2016

Arrowhead Pharmaceuticals Presents New Data on ARC-F12 and ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle

November 14, 2016

Arrowhead Pharmaceuticals Presents New Data on ARC-AAT

November 9, 2016

Arrowhead Pharmaceuticals Provides Update on Heparc-2004 Study

November 1, 2016

Arrowhead Pharmaceuticals to Present at Upcoming Conferences

October 20, 2016

Arrowhead Pharmaceuticals to Present Data on ARC-AAT at The Liver Meeting®

October 6, 2016

Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B

September 29, 2016

Amgen and Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations

September 7, 2016

Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521

September 6, 2016

Arrowhead Pharmaceuticals Initiates Phase 2 Study of ARC-AAT

September 1, 2016

Arrowhead Pharmaceuticals to Present at Upcoming September Conferences

August 12, 2016

Arrowhead Pharmaceuticals Closes $45 Million Private Offering

August 9, 2016

Arrowhead Reports Fiscal 2016 Third Quarter Results

August 9, 2016

Arrowhead Pharmaceuticals Prices $45 Million Private Offering

August 1, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Third Quarter Results

July 6, 2016

Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

June 9, 2016

Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521

June 3, 2016

Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference

May 10, 2016

Arrowhead Reports Fiscal 2016 Second Quarter Results

May 6, 2016

Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration

May 3, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Second Quarter Results

April 29, 2016

Arrowhead Pharmaceuticals to Present at Upcoming May Conferences

April 28, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521

April 18, 2016

Arrowhead Pharmaceuticals Presents Preclinical Data on Renal Cell Carcinoma Program at AACR 2016

April 13, 2016

Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The International Liver Congress™ 2016

April 6, 2016

Arrowhead Research Changes Name to Arrowhead Pharmaceuticals

March 30, 2016

Arrowhead to Present at Upcoming April Conferences

March 7, 2016

Arrowhead Presents Promising New Preclinical Data on ARC-F12 at AAAAI 2016

March 1, 2016

Arrowhead to Present at Upcoming March Conferences

February 16, 2016

Arrowhead to Present at Upcoming February Conferences

February 9, 2016

Arrowhead Reports Fiscal 2016 First Quarter Results

February 2, 2016

Arrowhead to Webcast Fiscal 2016 First Quarter Results

January 19, 2016

Arrowhead's ARC-AAT Granted EMA Orphan Drug Designation

January 7, 2016

Arrowhead Begins Dosing the Phase 2b MONARCH Combination Study of ARC-520 in Patients with Chronic Hepatitis B Infection

December 14, 2015

Arrowhead Reports Fiscal 2015 Year End Results

December 14, 2015

Arrowhead Added to NASDAQ Biotechnology Index®

December 7, 2015

Arrowhead to Webcast Fiscal 2015 Year End Results

December 7, 2015

Arrowhead's ARC-520 Leads to Consistent Immune Reactivation in Chimpanzees with Chronic Hepatitis B Infection

November 16, 2015

Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA

November 15, 2015

Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects with ARC-520 in Hepatitis B Infected Chimpanzees

November 11, 2015

Arrowhead to Present at Upcoming Conferences

October 20, 2015

Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015

October 14, 2015

Arrowhead Presents Overview of Its Broad RNAi Delivery Platform and Introduces New Subcutaneously Administered Format

October 5, 2015

Arrowhead to Present at Upcoming Conferences

September 24, 2015

Arrowhead Reports Peak Reduction in HBsAg of Up to 99% (1.9 log) After a Single Dose with Hepatitis B Candidate ARC-520 in Treatment Naïve Cohort of Phase 2a Study

September 11, 2015

Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery System

September 10, 2015

Arrowhead to Webcast Analyst Day Presentation on Hepatitis B Candidate ARC-520

August 5, 2015

Arrowhead to Present at Jefferies 2015 Hepatitis B Summit

August 4, 2015

Arrowhead Reports Fiscal 2015 Third Quarter Financial Results

July 28, 2015

Arrowhead to Report Fiscal 2015 Third Quarter Financial Results

July 8, 2015

Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand

July 2, 2015

Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency

June 17, 2015

Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520

June 10, 2015

Arrowhead Receives Orphan Drug Designation for ARC-AAT

May 27, 2015

Arrowhead to Present at Jefferies 2015 Healthcare Conference

May 11, 2015

Arrowhead Reports Fiscal 2015 Second Quarter Financial Results

May 6, 2015

Arrowhead Presents Data on Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic and Thromboembolic Diseases

May 5, 2015

Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT

May 4, 2015

Arrowhead to Report Fiscal 2015 Second Quarter Financial Results

April 30, 2015

Arrowhead Publishes Data on Advances in Subcutaneous siRNA Delivery

April 28, 2015

Arrowhead to Present at Upcoming Conferences

April 13, 2015

Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520

March 5, 2015

Arrowhead Acquires Novartis' RNAi Research and Development Portfolio

March 4, 2015

Arrowhead to Present at 2015 Barclays Global Healthcare Conference

February 23, 2015

Arrowhead Begins Phase 1 Trial of ARC-AAT for Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency

February 17, 2015

Arrowhead to Present at 2015 RBC Capital Markets' Global Healthcare Conference

February 9, 2015

Arrowhead Reports Fiscal 2015 First Quarter Financial Results

February 2, 2015

Arrowhead to Report Fiscal 2015 First Quarter Financial Results

January 12, 2015

Arrowhead Provides Update on IND for ARC-520 Phase 2b Study

December 29, 2014

CORRECTING and REPLACING Arrowhead Appoints Patrick O'Brien as General Counsel

December 15, 2014

Arrowhead Files IND for RNAi Therapeutic ARC-520 to Begin Phase 2b Multiple-Dose Studies in Chronic Hepatitis B Patients

December 4, 2014

Arrowhead Appoints Patrick O'Brien as General Counsel

November 25, 2014

Arrowhead Reports Fiscal 2014 Year End Financial Results

November 18, 2014

Arrowhead to Report Fiscal 2014 Fourth Quarter and Year End Financial Results

November 18, 2014

Arrowhead Files for Regulatory Permission to Begin Phase 1 Trial of RNAi Therapeutic ARC-AAT

November 14, 2014

Arrowhead to Present at Upcoming Conferences

November 10, 2014

Arrowhead Presents Data on ARC-520 and ARC-AAT at AASLD The Liver Meeting® 2014

October 9, 2014

Arrowhead Issues Open Letter to Shareholders

October 8, 2014

Arrowhead to Present ARC-520 Phase 2a Data in Late-Breaking Session at AASLD Liver Meeting® 2014

October 7, 2014

Arrowhead to Present at 10th Annual Meeting of the Oligonucleotide Therapeutics Society

September 30, 2014

Arrowhead Expands Management Team with Appointment of Susan Boynton as Vice President Global Regulatory Affairs

September 19, 2014

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference

August 12, 2014

Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520

July 31, 2014

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results

June 19, 2014

Arrowhead Announces New Clinical Candidate ARC-AAT for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

June 16, 2014

Arrowhead Research Set to Join Russell 3000 Index

June 13, 2014

Arrowhead Issues a Statement on Intellectual Property Protection for ARC-520

June 11, 2014

Arrowhead to Host Analyst Day to Discuss New Rare Liver Disease Candidate

June 10, 2014

Arrowhead to Present at Upcoming Investor Conferences

May 29, 2014

Arrowhead to Present at the Jefferies 2014 Global Healthcare Conference

May 6, 2014

Arrowhead Reports Fiscal 2014 Second Quarter Financial Results

May 6, 2014

Arrowhead to Present at Upcoming Scientific Conferences

May 1, 2014

Arrowhead to Present at Deutsche Bank 39th Annual Health Care Conference

April 29, 2014

Arrowhead to Report Fiscal 2014 Second Quarter Financial Results

April 1, 2014

Arrowhead Completes Enrollment of First Cohort in Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520

March 24, 2014

Arrowhead Begins Dosing in Phase 2a Trial of RNAi Therapeutic ARC-520 in Chronic Hepatitis B Patients

March 10, 2014

Arrowhead to Present at Barclays Global Healthcare Conference

March 3, 2014

Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520

February 24, 2014

Arrowhead Closes Underwritten Offering with Gross Proceeds of $120 Million

February 20, 2014

Arrowhead to Present at RBC Capital Markets' Global Healthcare Conference

February 19, 2014

Arrowhead Announces Pricing of Underwritten Offering of Common Stock

February 18, 2014

Arrowhead Announces Proposed Underwritten Offering of Common Stock

February 4, 2014

Arrowhead Reports Fiscal 2014 First Quarter Financial Results

February 4, 2014

Arrowhead to Participate in Panel Discussions at 16th Annual BIO CEO & Investor Conference

January 28, 2014

Arrowhead to Report Fiscal 2014 First Quarter Financial Results

December 18, 2013

Arrowhead Reports Fiscal 2013 Fourth Quarter and Year-End Financial Results

December 11, 2013

Arrowhead to Report Fiscal 2013 Fourth Quarter and Year-End Financial Results

December 9, 2013

Arrowhead Presents Phase 1 Data on ARC-520 at HepDART 2013

December 6, 2013

Arrowhead Research Corporation Announces Proposed Public Offering of Common Stock and Warrants

November 26, 2013

Arrowhead to Present at Piper Jaffray Healthcare Conference

November 25, 2013

Arrowhead Submits Application to Begin Phase 2a Trial of ARC-520 for the Treatment of Chronic Hepatitis B Infection

November 7, 2013

Arrowhead to Present at Upcoming Conferences

November 4, 2013

Arrowhead Presents Data Suggesting ARC-520 Induces Therapeutic Flare in Chronic Hepatitis B

October 25, 2013

Arrowhead Announces Inducement Grants Under NASDAQ Rule 5635(c)(4)

October 18, 2013

Arrowhead to Present at Upcoming Conferences

October 14, 2013

Arrowhead Closes Private Offering with Net Proceeds of $60 Million

October 8, 2013

Arrowhead Prices At-Market Private Offering for $60 Million Net Proceeds

October 8, 2013

Arrowhead Completes Enrollment in Phase 1 Study of ARC-520 for the Treatment of Chronic Hepatitis B

September 19, 2013

Arrowhead Promotes David Lewis to Chief Scientific Officer

August 7, 2013

Arrowhead Reports Fiscal 2013 Third Quarter Financial Results

July 31, 2013

Arrowhead to Report Fiscal 2013 Third Quarter Financial Results

July 23, 2013

Arrowhead Begins Phase 1 Trial of RNAi Therapeutic ARC-520 for Treatment of Chronic Hepatitis B Infection

June 13, 2013

Arrowhead to Present at Upcoming Scientific Conferences

May 28, 2013

Arrowhead Files to Begin Phase 1 Trial of RNAi Therapeutic ARC-520 Against Chronic Hepatitis B Infection

May 10, 2013

Arrowhead to Present at Upcoming Scientific Conferences

May 9, 2013

Arrowhead Reports Fiscal 2013 Second Quarter Financial Results

May 7, 2013

Arrowhead Receives Patent Allowance for DPC siRNA Delivery System with Peptide Backbone

May 6, 2013

Arrowhead Closes $36 Million Private Offering

May 2, 2013

Arrowhead to Report Fiscal 2013 Second Quarter Financial Results

April 29, 2013

Arrowhead Prices $36 Million Private Offering

April 24, 2013

Arrowhead to Present at Needham Healthcare Conference

April 24, 2013

Arrowhead to Present at Master Investor 2013

March 25, 2013

Arrowhead Induces 90% Reduction in Hepatitis B Antigens in Chimpanzee with Chronic Infection: Data Follow Previous Report of Reduction in Viral DNA

March 14, 2013

Arrowhead RNAi Candidate ARC-520 Induces Greater than 90% Reduction in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis B

March 7, 2013

Arrowhead to Host Analyst Event in New York to Discuss RNAi-based Hepatitis B Candidate ARC-520

March 7, 2013

Arrowhead to Host Analyst Event in New York to Discuss RNAi-based Hepatitis B Candidate ARC-520

February 28, 2013

Arrowhead Receives Notice of Patent Allowance for New Protease Sensitive Masking Chemistry for DPC siRNA Delivery System

February 26, 2013

Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus

February 13, 2013

Arrowhead Reports Fiscal 2013 First Quarter Financial Results

February 6, 2013

Arrowhead to Report Fiscal 2013 First Quarter Financial Results

February 1, 2013

Arrowhead to Present at Upcoming Scientific Conferences

January 25, 2013

Arrowhead Announces Pricing of a Public Offering of Common Stock and Warrants

January 24, 2013

Arrowhead Research Corporation Announces Proposed Public Offering of Common Stock and Warrants

December 20, 2012

Arrowhead Reports Fiscal 2012 Fourth Quarter and Year-End Financial Results

December 18, 2012

Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics

December 14, 2012

Arrowhead to Report Fiscal 2012 Fourth Quarter and Year-End Financial Results

December 7, 2012

Arrowhead Announces Pricing of a Public Offering of Common Stock and Warrants

November 27, 2012

Arrowhead Publishes First Ever Cholesterol-siRNA Mediated Gene Knockdown in Primates and Novel DPC Co-Injection Strategy

November 13, 2012

Arrowhead Creates Hepatitis B Clinical Advisory Board and Names Dr. Robert Gish Chairman

November 12, 2012

Arrowhead Research to Present at BIO-Europe 2012

October 29, 2012

Arrowhead Presents Data Showing 99% Target Knockdown in Monkeys Without Toxicity Using Subcutaneous Formulation of Dynamic Polyconjugate siRNA Delivery System

October 16, 2012

Arrowhead Research Receives Notice of Patent Allowance for New Formulation of DPC siRNA Delivery System Showing 500-Fold Increase in Potency

September 5, 2012

Arrowhead to Present at Rodman and Renshaw Annual Global Investment Conference

August 30, 2012

Arrowhead Completes Enrollment in Phase 1b Trial of RNAi Drug Candidate CALAA-01

August 13, 2012

Arrowhead Raises $6.2 Million through Registered Direct Offering of Common Stock and Warrants

August 13, 2012

Arrowhead Reports Fiscal 2012 Third Quarter Financial Results

August 9, 2012

Arrowhead Research to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference

August 7, 2012

Arrowhead to Report Fiscal 2012 Third Quarter Financial Results

July 11, 2012

Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide® in a Phase 1 Clinical Trial

June 26, 2012

Arrowhead Announces New Study Demonstrating Rapid Improvement in Pro-Diabetic Metabolic Markers with Anti-Obesity Drug Candidate, Adipotide®

June 6, 2012

Arrowhead Research Advances ARC-520 into IND-Enabling Studies for the Treatment of Hepatitis B and Provides Guidance on Development Timeline

May 22, 2012

Arrowhead Presents Data on DPC System at TIDES 2012

May 9, 2012

Arrowhead Presents Data on DPC System and Hepatitis B Program at CLINAM 2012

May 8, 2012

Arrowhead Reports Fiscal 2012 Second Quarter Financial Results

May 3, 2012

Arrowhead to Present at Series of Upcoming Scientific Conferences

May 1, 2012

Arrowhead to Report Fiscal 2012 Second Quarter Financial Results

April 11, 2012

Arrowhead Research Corporation Acquires Alvos Therapeutics and Proprietary Library of Targeting Peptides

March 7, 2012

Arrowhead Releases White Paper on Hepatitis B Virus and Potential RNAi Treatment

March 5, 2012

Arrowhead Research Corporation and Axolabs GmbH Enter into Strategic Alliance and Master Services Agreement for RNAi Therapeutics

February 29, 2012

Arrowhead Announces Patent Issuance Covering siRNA Inhibitors of HIF-2α (EPAS1)

February 9, 2012

Arrowhead Reports Fiscal 2012 First Quarter Financial Results

February 2, 2012

Arrowhead to Report Fiscal 2012 First Quarter Financial Results

January 5, 2012

Alnylam and Arrowhead Form Collaboration and Licensing Agreement

January 4, 2012

Arrowhead Announces FDA Clearance to Initiate Adipotide™ Phase I Clinical Trial

December 20, 2011

Arrowhead Reports Fiscal 2011 Fourth Quarter and Year-End Financial Results

December 19, 2011

Arrowhead Appoints Michael S. Perry, DVM, Ph.D. to Board of Directors

December 15, 2011

Arrowhead to Report Fiscal 2011 Fourth Quarter and Year-End Financial Results

November 27, 2011

Arrowhead Research Publishes White Paper on RNAi Delivery Technology Acquired from Roche

November 23, 2011

Arrowhead Research Appoints Drs. David Lewis and David Rozema to Lead Operations at Madison, WI Facility

November 16, 2011

Arrowhead Research Announces 1-for-10 Reverse Stock Split

November 14, 2011

Leonardo Biosystems Receives Second $1.25 Million Investment from the Texas Emerging Technology Fund

November 10, 2011

Arrowhead Research Subsidiary Ablaris Therapeutics Data Published in Science Translational Medicine Demonstrates Weight Loss in Obese Monkeys

November 3, 2011

Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer

November 2, 2011

Vascular Research Further Validates the Drug Development Programs of Arrowhead Research Subsidiary Ablaris Therapeutics and Alvos Therapeutics

October 27, 2011

Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer

October 24, 2011

Arrowhead Research Corporation Acquires Roche RNA Assets and Site

October 4, 2011

Arrowhead Research Corporation Completes $5.5 Million Private Placement

August 8, 2011

Arrowhead Reports Fiscal 2011 Third Quarter Financial Results

August 1, 2011

Arrowhead Research to Report Fiscal 2011 Third Quarter Financial Results and Host Conference Call on Monday, August 8, 2011

July 26, 2011

Arrowhead Research Announces Oncology Expert Timothy J. Triche to Join Calando Scientific Advisory Board

June 21, 2011

Arrowhead Research to Present at Two Nanomedicine-Focused Events in London

June 16, 2011

Arrowhead Research President & CEO Christopher Anzalone Featured in The Wall Street Transcript Interview

June 9, 2011

Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ $1.00 Minimum Bid Requirement

May 12, 2011

Arrowhead Reports Fiscal 2011 Second Quarter Financial Results

May 4, 2011

Arrowhead Research to Report Fiscal 2011 Second Quarter Financial Results and Host Conference Call on Thursday, May 12, 2011

May 3, 2011

Arrowhead Research to Present at the 2011 MDB Capital Group Bright Lights Conference on May 10

April 27, 2011

ARROWHEAD RESEARCH ANNOUNCES RNAI LEADER JOHN J. ROSSI, PH.D. TO JOIN CALANDO SCIENTIFIC ADVISORY BOARD

April 6, 2011

ARROWHEAD RESEARCH INCREASES OWNERSHIP IN ABLARIS TO 64%

March 8, 2011

Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16

February 10, 2011

ARROWHEAD REPORTS FISCAL 2011 FIRST QUARTER FINANCIAL RESULTS

February 9, 2011

Arrowhead Research to Present at the 13th Annual BIO CEO & Investor Conference

February 6, 2011

Arrowhead Research to Report Fiscal 2011 First Quarter Financial Results and Host Conference Call on Thursday, February 10, 2011

January 18, 2011

Arrowhead Subsidiary Unidym, Inc. Acquired by Wisepower Co., Ltd. for up to $140 million earn-out plus $5 million upfront

January 8, 2011

Arrowhead Increases Investment in RNAi Subsidiary Calando Pharmaceuticals

584 Results